Abstract 6119
Background
Cancer nursing is required to identify potential advances in nursing practice, assess their relevance for ones own particular clinical situation, gather opinion on any potential change in practice (both locally and farther afield), integrate this into practice, evaluate success and then disseminate the learning from this process. Until relatively recently this process could be reasonably laborious and slow moving. However, the advent of social media sites and software and their use in nursing has streamlined this process making the gathering, group analysis and dissemination of clinical information faster and more intuitive. This study considers the authors own experience in using two social media sites (Twitter and Facebook) to gather and share clinical infomation as part of the UK Oncology Nursing Society and when setting up a new Members Interest Group for UK Lead Cancer Nurses.
Methods
This piece describes the use of Twitter and Facebook group as a professional tool to -: 1) Gather cancer nursing opinion on a particular subject (case study - Streamlining MDT Working in England and the contrubution of specialist Nursing) - potentially a ’digitall Delphi Technique’ using Twitter and Facebook 2) Build group cohesion, ask clinical questions, share information and practice and build relationships within a newly established UK group of Lead Cancer Nurses. The experiences of UKONS members of using social media professionally will be gathered, the clinical effectivenes of using social media to gather nursing opinion on a particular nursing problem (streamlining MDT working) will be analysed.
Results
The experiences of cancer nurses in using social media in professional settings will be presented as part of an overall narrative and key themes will be presented and discussed Number and range of responses to a clinical question posed on social media will be presented with consideration of how effective a tool Twitter is in gathering clinical opinion and driving improvement. Ths will be presented numerically and graphically.
Conclusions
The positive impact of the professional use of social media will be presented. Potential uses and fine tuning of these tools in cancer nursing will be considered Potential pitfalls and negative effects will also be considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract